Transport of Amino Acid Esters and the Amino-Acid-Based Prodrug Valganciclovir by the Amino Acid Transporter ATB0,+
Tóm tắt
Purpose. The purpose of this study was to analyze the transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the Na+/Cl−-coupled amino acid transporter ATB0,+.
Methods. The interaction of amino acid esters and valganciclovir with the cloned rat ATB0,+ was evaluated in a mammalian cell expression system and in the Xenopus oocyte expression system.
Results. In mammalian cells, expression of ATB0,+ induced glycine uptake. This uptake was inhibited by valine and its methyl, butyl, and benzyl esters. The benzyl esters of other neutral amino acids were also effective inhibitors. Valganciclovir, the valyl ester of ganciclovir, was also found to inhibit ATB0,+-mediated glycine uptake competitively. Exposure of ATB0,+-expressing oocytes to glycine induced inward currents. Exposure to different valyl esters (methyl, butyl, and benzyl), benzyl esters of various neutral amino acids, and valganciclovir also induced inward currents in these oocytes. The current induced by valganciclovir was saturable with a K0.5 value of 3.1 ± 0.7 mM and was obligatorily dependent on Na+ and Cl−. The Na+:Cl−:valganciclovir stoichiometry was 2 or 3:1:1.
Conclusions Amino acid esters and the amino-acid-based prodrug valganciclovir are transported by ATB0,+. This shows that ATB0,+ can serve as an effective delivery system for amino acid-based prodrugs.
Tài liệu tham khảo
M. Palacin, R. Estevez, J. Bertran, and A. Zorzano. Molecular biology of mammalian plasma membrane amino acid transporters. Physiol. Rev. 78:969-1054 (1998).
V. Ganapathy, K. Inoue, P. D. Prasad, and M. E. Ganapathy. Cellular uptake of amino acids: system and regulation. In L. A. Cynober (ed.), Amino Acid Metabolism and Therapy in Health and Nutritional Diseases, CRC Press, Boca Raton, FL, 2004, pp.63-78.
T. Hatanaka, W. Huang, T. Nakanishi, C. C. Bridges, S. B. Smith, P. D. Prasad, M. E. Ganapathy, and V. Ganapathy. Transport of D-serine via the amino acid transporter ATB0,+ expressed in the colon. Biochem. Biophys. Res. Commun. 291:291-295 (2002).
J. L. Sloan and S. Mager. Cloning and functional expression of a human Na+ and Cl--dependent neutral and cationic amino acid transporter B0,+. J. Biol. Chem. 274:23740-23745 (1999).
T. Nakanishi, T. Hatanaka, W. Huang, P. D. Prasad, F. H. Leibach, M. E. Ganapathy, and V. Ganapathy. Na+-and Cl--coupled active transport of carnitine by the amino acid transporter ATB0,+ from mouse colon expressed in HRPE cells and Xenopus oocytes. J. Physiol. (Lond.) 532:297-304 (2001).
T. Hatanaka, T. Nakanishi, W. Huang, F. H. Leibach, P. D. Prasad, V. Ganapathy, and M. E. Ganapathy. Na+-and Cl--coupled active transport of nitric oxide synthase inhibitors via the amino acid transport system ATB0,+. J. Clin. Invest. 107:1035-1043 (2001).
T. Hatanaka, M. Haramura, Y. J. Fei, S. Miyauchi, C. C. Bridges, P. S. Ganapathy, S. B. Smith, V. Ganapathy, and M. E. Ganapathy. Transport of amino acid-based prodrugs by the Na+-and Cl--coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J. Pharmacol. Exp. Ther. 308:1138-1147 (2004).
P. de Miranda and T. C. Burnette. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab. Dispos. 22:55-59 (1994).
H. Steingrimsdottir, A. Gruber, C. Palm, G. Grimfors, M. Kalin, and S. Eksborg. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrob. Agents Chemother. 44:207-209 (2000).
F. Brown, L. Banken, K. Saywell, and I. Arum. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV-and CMV-seropositive volunteers. Clin. Pharmacokinet. 37:167-176 (1999).
M. D. Pescovitz, J. Rabkin, R. M. Merion, C. V. Paya, J. Pirsch, R. B. Freeman, J. O'Grady, C. Robinson, Z. To, K. Wren, L. Banken, W. Buhles, and F. Brown. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother. 44:2811-2815 (2000).
H. Han, R. L. de Vrueh, J. K. Rhie, K. M. Covitz, P. L. Smith, C. P. Lee, D. M. Oh, W. Sadee, and G. L. Amidon. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 15:1154-1159 (1998).
G. M. Friedrichsen, W. Chen, M. Begtrup, C. P. Lee, P. L. Smith, and R. T. Borchardt. Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligo-peptide transporter in Caco-2 cells. Eur. J. Pharm. Sci. 16:1-13 (2002).
B. S. Anand and A. K. Mitra. Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Pharm. Res. 19:1194-1202 (2002).
K. Sawada, T. Terada, H. Saito, Y. Hashimoto, and K. I. Inui. Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2. J. Pharmacol. Exp. Ther. 291:705-709 (1999).
M. E. Ganapathy, W. Huang, H. Wang, V. Ganapathy, and F. H. Leibach. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun. 246:470-475 (1998).
M. Sugawara, W. Huang, Y. J. Fei, F. H. Leibach, V. Ganapathy, and M. E. Ganapathy. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 89:781-789 (2000).